ADMP= MC $33 M-PDUFA DATE Oct.31...the most underpriced and hottest fda play for the year .. they have already a marketed drug partnered with Sanodz (Novartis) which targeting a $1.5 BILLION market the drug was full lauchned in Q2 this year = POTENTIAL 10 BAGGER HERE GUYS ..
Admamis Pharma (ADMP)
Cash: $17 million
ZIMHI (naloxone) injection
Indication–Opioid Overdose Addressable Market -$330 million
FDA action date Oct. 31, 2019
SYMJEPI (epinephrine) injection
Addressable Market -$1.5 billion
First products using patented, FDA-approved injection device
Both doses (0.3mg and 0.15mg) are FDA approved
Sandoz a division of Novartis –commercial partner in U.S.
Commercial deal terms –50% of net profits, upfront fee and potential performance-based milestone payments
Near-Term Target Milestones
FDA action date (PDUFA) of Oct. 31, 2019 on NDA for ZIMHI
Pursuing potential partnerships for SYMJEPI (ex-US) and ZIMHI product candidate
Continued launch of SYMJEPI in U.S. –retail and SYMJEPI low dose launches pending